KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2025)

Historic Work In Process for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q3 2025 value amounting to $35.5 million.

  • Alnylam Pharmaceuticals' Work In Process fell 4918.2% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 4918.2%. This contributed to the annual value of $65.0 million for FY2024, which is 1557.24% down from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Work In Process is $35.5 million, which was down 4918.2% from $43.8 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Work In Process high stood at $116.7 million for Q2 2023, and its period low was $23.6 million during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Work In Process averaged around $73.4 million, with its median value being $76.1 million (2024).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Work In Process surged by 52506.66% in 2021 and then plummeted by 4918.2% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Work In Process (Quarter) stood at $100.9 million in 2021, then grew by 12.72% to $113.8 million in 2022, then crashed by 32.36% to $77.0 million in 2023, then dropped by 15.57% to $65.0 million in 2024, then plummeted by 45.36% to $35.5 million in 2025.
  • Its Work In Process was $35.5 million in Q3 2025, compared to $43.8 million in Q2 2025 and $54.0 million in Q1 2025.